ArticleVeterinary world2025
A lung cancer mouse model system based on an inbred C3H strain: Ultrasound imaging, pathological analysis, and proteomic biomarker identification.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of pericardial disruption on heart function and remodeling after myocardial infarction in mice.The international journal of cardiovascular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Lung cancer remains a leading cause of global mortality, necessitating robust animal models for research into its mechanisms and therapeutic options. This study aimed to develop and validate a novel lung cancer mouse model using the inbred C3H strain through intraperitoneal (I.P) injection of benzo(a)pyrene, offering insights into hematology, pathology, imaging, and proteomic biomarkers. Materials and Methods: Twelve male inbred C3H mice were assigned to non-treated and treatment groups, with the latter receiving 100 mg/kg body weight of benzo(a)pyrene intraperitoneally. Tumor development was monitored for 15 days using hematological analysis, ultrasound imaging (Vevo F2), histopathological assessment, and proteomic profiling through liquid chromatography-high-resolution mass spectrometry. Results: Hematological analysis indicated a decrease in white blood cells, lymphopenia, and neutropenia, while red blood cells, hemoglobin, and platelets remained within normal ranges. Ultrasound imaging revealed tumor formation as hypoechoic areas with irregular patterns on the lung surface. The histological analysis highlighted lymphocyte infiltration, alveolar wall thickening, fibroelastosis, and dysplastic changes in the bronchial epithelium. Proteomic profiling identified specific biomarkers associated with lung cancer, including A disintegrin and metalloproteinase with thrombospondin motifs 12, abnormal spindle, adducin-3, adhesion G protein-coupled receptor, Agrin, apoptotic chromatin condensation inducer 1, rapidly accelerated fibrosarcoma isoforms B oncogene, breast cancer gene 2, hypoxia-induced gene-1, leucine-rich repeat-containing 2, leucine-rich repeat kinase 2, leucine-rich repeat-containing protein 2 isoform X2, membrane-spanning 4-domains, subfamily A, proto-oncogene tyrosine-protein kinase Src, rat sarcoma virus-related protein 14, squamous cell carcinoma antigen, and transcription intermediary factor 1-alpha. Conclusion: The I.P administration of benzo(a)pyrene in C3H mice effectively induced lung cancer, demonstrating significant pathological and biomarker changes. This model provides a valuable platform for investigating lung cancer mechanisms, evaluating new therapeutic approaches, and potentially shortening the timeframe required to establish reliable animal models for preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.